Affiliation:
1. Molecular Physiology Laboratory, Centre for Atherothrombosis &
Metabolic Disease, Hull York Medical School, University of Hull
Abstract
AbstractDoxorubicin is an anti-neoplasmic drug that prevents DNA replication but induces
senescence and cellular toxicity. Intensive research has focused on strategies
to alleviate the doxorubicin-induced skeletal myotoxicity. The aim of the
present review is to critically discuss the relevant scientific evidence about
the role of exercise and growth factor administration and offer novel insights
about newly developed-tools to combat the adverse drug reactions of doxorubicin
treatment on skeletal muscle. In the first part, we discuss current data and
mechanistic details on the impact of doxorubicin on skeletal myotoxicity. We
next review key aspects about the role of regular exercise and the impact of
growth factors, administered either pharmacologically or via genetic
interventions. Future strategies such as combination of exercise and growth
factor administration remain to be established to combat the
pharmacologically-induced myotoxicity.
Subject
Orthopedics and Sports Medicine,Physical Therapy, Sports Therapy and Rehabilitation
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献